Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$22.95 +0.7%	$18.68	$13.40 ▼ $25.23	$3.84B	0.65	1.94 million shs	2.41 million shs
PSTX Poseida Therapeutics	$9.50	$9.48	$2.32 ▼ $9.67	$928.85M	1.63	1.02 million shs	N/A
RARE Ultragenyx Pharmaceutical	$37.35 +1.9%	$36.37	$29.59 ▼ $60.37	$3.53B	0.25	838,729 shs	1.02 million shs
RNA Avidity Biosciences	$29.32 -0.1%	$30.39	$21.51 ▼ $56.00	$3.53B	0.95	1.41 million shs	990,714 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+5.57%	+5.81%	+36.69%	+54.34%
PSTX Poseida Therapeutics	0.00%	0.00%	0.00%	0.00%	+259.85%
RARE Ultragenyx Pharmaceutical	0.00%	-4.94%	0.00%	-4.67%	-0.19%
RNA Avidity Biosciences	0.00%	-8.77%	-7.33%	-4.93%	-23.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.6831 of 5 stars	3.3	1.0	0.0	2.6	4.2	2.5
PSTX Poseida Therapeutics	0.4956 of 5 stars	1.0	0.0	4.6	0.0	0.8	0.0
RARE Ultragenyx Pharmaceutical	4.222 of 5 stars	3.5	3.0	3.8	2.4	2.5	0.6
RNA Avidity Biosciences	2.1067 of 5 stars	4.5	0.0	0.0	2.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.69	Moderate Buy	$26.79	16.71% Upside
PSTX Poseida Therapeutics	2.00	Hold	$9.50	N/A
RARE Ultragenyx Pharmaceutical	2.92	Moderate Buy	$88.77	137.67% Upside
RNA Avidity Biosciences	3.06	Buy	$66.56	127.02% Upside

Current Analyst Ratings Breakdown

Latest PSTX, ACAD, RNA, and RARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	RNA Avidity Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
6/11/2025	RNA Avidity Biosciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$65.00
6/10/2025	RNA Avidity Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $75.00
6/10/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $59.00
6/10/2025	RNA Avidity Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $59.00
6/9/2025	RNA Avidity Biosciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$48.00 ➝ $54.00
6/9/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $75.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
5/28/2025	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.01	$0.70 per share	32.56	$4.40 per share	5.22
PSTX Poseida Therapeutics	$150.86M	6.16	N/A	N/A	$1.08 per share	8.80
RARE Ultragenyx Pharmaceutical	$560.23M	6.30	N/A	N/A	$2.76 per share	13.53
RNA Avidity Biosciences	$10.90M	324.19	N/A	N/A	$11.94 per share	2.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	16.75	30.20	4.91	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
PSTX Poseida Therapeutics	-$123.43M	-$0.63	N/A	N/A	N/A	-40.28%	-72.26%	-21.53%	N/A
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)

Latest PSTX, ACAD, RNA, and RARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PSTX Poseida Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
PSTX Poseida Therapeutics	0.68	3.20	3.20
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24
RNA Avidity Biosciences	N/A	16.91	16.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
PSTX Poseida Therapeutics	46.87%
RARE Ultragenyx Pharmaceutical	97.67%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
PSTX Poseida Therapeutics	2.90%
RARE Ultragenyx Pharmaceutical	5.50%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
PSTX Poseida Therapeutics	260	97.77 million	94.94 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	94.54 million	89.34 million	Optionable
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable

PSTX, ACAD, RNA, and RARE Headlines

Recent News About These Companies

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $27,548.64 in Stock

June 19 at 8:01 AM | insidertrades.com

Wolfe Research Begins Coverage on Avidity Biosciences (NASDAQ:RNA)

June 19 at 1:43 AM | americanbankingnews.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Kathleen P. Gallagher Sells 911 Shares

June 18 at 8:52 PM | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Trading Up 4.1% - Here's Why

June 17 at 1:35 PM | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated at Wolfe Research

June 17 at 8:43 AM | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential

June 16, 2025 | investing.com

Avidity Biosciences (NASDAQ:RNA) Shares Down 3.5% - Here's What Happened

June 16, 2025 | marketbeat.com

Assenagon Asset Management S.A. Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 15, 2025 | marketbeat.com

Rhumbline Advisers Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 14, 2025 | marketbeat.com

GAMMA Investing LLC Has $1.96 Million Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 14, 2025 | marketbeat.com

Leerink Partnrs Analysts Decrease Earnings Estimates for RNA

June 14, 2025 | americanbankingnews.com

W. Michael Flanagan Sells 20,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

June 12, 2025 | marketbeat.com

Leerink Partnrs Has Pessimistic View of RNA FY2026 Earnings

June 12, 2025 | marketbeat.com

Raymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy Recommendation

June 12, 2025 | msn.com

Barclays Forecasts Strong Price Appreciation for Avidity Biosciences (NASDAQ:RNA) Stock

June 12, 2025 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Stock Price Expected to Rise, Citigroup Analyst Says

June 12, 2025 | americanbankingnews.com

Analysts Offer Predictions for RNA FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James

June 11, 2025 | msn.com

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

June 11, 2025 | prnewswire.com

Cantor Fitzgerald Weighs in on RNA FY2026 Earnings

June 11, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at Raymond James

June 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
BigBear.ai: Risky AI Stock or Defense Tech Opportunity?
By Jeffrey Neal Johnson | May 28, 2025
View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?
These 3 Stocks Are Buying Back Billions in Shares
By Leo Miller | June 3, 2025
View These 3 Stocks Are Buying Back Billions in Shares

PSTX, ACAD, RNA, and RARE Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.95 +0.15 (+0.66%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$22.94 -0.01 (-0.05%)

As of 06/18/2025 07:57 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Poseida Therapeutics NASDAQ:PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$37.35 +0.69 (+1.88%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$37.36 +0.02 (+0.04%)

As of 06/18/2025 04:33 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Avidity Biosciences NASDAQ:RNA

$29.32 -0.04 (-0.14%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$29.06 -0.27 (-0.90%)

As of 06/18/2025 07:11 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time